Elekta Unveils Strategic Growth Plans and Product Innovations at Investor Update

The latest update is out from Elekta AB ( ($SE:EKTA.B) ).

Elekta’s Investor Update in Stockholm showcased its innovative portfolio and strategic growth plans, including restoring gross margin and achieving a 14% EBIT margin. The company highlighted its proactive order review, resulting in a SEK 4.9 billion cancellation, and discussed the positive market reception of its latest products, emphasizing the importance of adaptive radiation therapy in improving clinical outcomes.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

More about Elekta AB

Elekta is a leader in precision radiation therapy, dedicated to providing the best cancer care through sustainable, outcome-driven, and cost-efficient solutions. With a global team of 4,500 employees, Elekta is headquartered in Stockholm, Sweden, and operates in over 40 countries, focusing on advancing cancer care technology.

Average Trading Volume: 1,336,135

Current Market Cap: SEK19.09B

For a thorough assessment of EKTA.B stock, go to TipRanks’ Stock Analysis page.